Biomarkers Market Analysis And Segment Forecasts To 2024
Phone No.: +1 (214) 884-6817 sales@orbisresearch.com
Email id:
Biomarkers Market Analysis And Segment Forecasts To 2024 The global biomarkers market is expected to reach over USD 78.2 billion by 2024, according to a new report by Grand View Research, Inc. The growing demand for companion diagnostics and the rising adoption of personalized medicine are the key factors propelling the growth of the biomarkers market. The increasing need of disease-specific biomarkers for the development of diagnostics, the increasing R&D funding, and the rising prevalence of oncology and cardiovascular-based diseases are anticipated to create significant opportunities for the market growth during the forecast period. Browse the report: http://www.orbisresearch.com/reports/index/biomarkers-market-analysis-bytype-safety-efficacy-validation-by-application-diagnostics-drug-development-personalizedmedicine-by-disease-oncology-cardiovascular-neurology-immunology-and-segment-forecasts-to2024 The spiraling population and the upward trend in the adoption of sedentary lifestyles are expected to provide the industry with a huge target population base. Government grants and research funding for the discovery and development of novel biomarkers are the other factors accentuating the market growth. The introduction of the biomarker-based diagnostic kits for screening high-risk population coupled with the growing prevalence of genetic disorders is also anticipated to increase the client base for this market.
Phone No.: +1 (214) 884-6817
Email id: sales@orbisresearch.com
Biomarkers Market Analysis And Segment Forecasts To 2024 Major players include Roche Diagnostics Ltd., Abbott Laboratories, Inc., Agilent Technologies, Inc., Epigenomics AG, GE Healthcare, Johnson and Johnson, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, Qiagen, Inc., Merck& Co., Inc., and others. Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/106370 Market participants are ensuring stability by fundingthe growing R&D initiatives and focusing on the developing countries through the expansion and introduction of novel biomarker diagnostics.In 2015, Pfizer, Inc. developed a lung cancer therapy drug, Crizotinib used in non-small cell lung cancer therapy associated with ALK fusions.
Phone No.: +1 (214) 884-6817
Email id: sales@orbisresearch.com
Biomarkers Market Analysis And Segment Forecasts To 2024 About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors accross the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817 enquiry@orbisresearch.com sales@orbisresearch.com Phone No.: +1 (214) 884-6817
Email id: sales@orbisresearch.com